Reconstitution and Storage of Tesamorelin: How to Properly Prepare and Store the Peptide

Tesamorelin is usually reconstituted by slowly adding bacteriostatic water (BAC water) or the supplied sterile diluent to the lyophilised peptide powder, followed by gentle swirling of the vial until completely dissolved and a clear solution is obtained [1–3]. Lyophilised means freeze-dried, which helps to maintain the stability of the peptide before mixing. Clinical preparations of tesamorelin are supplied as a lyophilised powder, which must be dissolved before subcutaneous injection.

As tesamorelin is a peptide-based medication, careful handling during reconstitution is important for maintaining peptide stability and reducing the risk of degradation. Most preparation protocols recommend slowly injecting the diluent down the inside wall of the vial rather than directing the stream directly onto the powder with force. Vigorous shaking is generally avoided as over-mixing can contribute to peptide breakdown, solution foaming, or damage to the peptide’s structure [1,3].

The general process for reconstituting tesamorelin typically involves the following steps:

• Wash hands thoroughly and prepare a clean workspace.
• Clean the tesamorelin vial and the BAC water vial using alcohol swabs.
• Draw the required amount of bacteriostatic water into a sterile syringe.
• Slowly inject water into the vial of tesamorelin.
• Allow the powder to dissolve naturally, gently rotating the vial if necessary.
• Avoid aggressive shaking.
• Chill the solution in the refrigerator if it will not be used immediately.

Following proper reconstitution, the tesamorelin solution should generally be clear and colourless. If the solution remains very cloudy, contains undissolved particles, changes colour, or forms undissolved clumps, this may indicate improper storage, instability, or contamination.

Clinical trials using tesamorelin have utilised subcutaneous injections after reconstitution according to the manufacturer's instructions, most commonly at a dose of 2 mg daily in studies of HIV-associated lipodystrophy and hepatic steatosis [4–7].

How much BAC water for Tesamorelin? Guide for 5 mg, 10 mg and 20 mg vials

The amount of bacteriostatic water (BAC water) used to reconstitute tesamorelin can vary depending on the preferred concentration and injection volume, however many popular preparation methods utilise approximately 1–3 mL of BAC water for 5 mg or 10 mg vials to facilitate accurate dosing [1–3]. Clinical trials have primarily standardised tesamorelin by dose alone rather than a single universal reconstitution volume.

For vials of tesamorelin 5 mg, common reconstitution methods include:

• 1 mL BAC water for a more concentrated solution.
• 2 mL BAC water for easier dosing and milder injections.

For fiolles of tesamorelin 10 mg, commonly mentioned preparation methods include:

• 2 mL BAC water.
• 3 mL BAC water, which is often mentioned in peptide preparation protocols.

For tesamorelin vials of 20 mg, some protocols use:

• Approximately 4–5 mL of BAC water depending on the desired concentration and dosage schedule.

The main purpose of reconstitution is to create a solution from which the prescribed dose can be accurately measured. The amount of BAC water added does not change the total amount of tesamorelin in the vial. It only changes the concentration of the final solution and the volume of liquid administered with each dose.

Clinical trials have most commonly used a dose of 2 mg of tesamorelin once daily administered subcutaneously [4–8]. A subcutaneous injection means the drug is injected into the fatty tissue directly beneath the skin.

When preparing tesamorelin:

• Slowly inject BAC water into the vial.
• Gently swirl the vial rather than shaking it vigorously.
• Ensure the solution becomes clear after complete dissolution.

Some commercial tesamorelin preparations contain manufacturer-specific diluents and reconstitution instructions; therefore, such instructions should always take precedence over general peptide preparation practices [1,2].

Po przywróceniu, Tesamorelin należy przechowywać w lodówce w temperaturze od 2°C do 8°C.

After reconstitution, tesamorelin is typically stored in a refrigerator at approximately 2–8°C (36–46°F) to help maintain peptide stability and reduce its degradation [1–3]. Proper refrigeration is important, as peptide compounds such as tesamorelin can gradually lose stability when exposed to heat, repeated temperature fluctuations, or prolonged storage at room temperature.

Before reconstitution, lyophilised tesamorelin powder often remains stable at controlled room temperature if protected from excessive heat, humidity, and direct light [1, 2]. However, once mixed with BAC water or another diluent, refrigeration becomes significantly more important to maintain the integrity of the peptide solution.

General storage recommendations typically include:

• Store reconstituted tesamtrorelin in a refrigerator at 2–8°C.
• Keep the vial away from direct light.
• Avoiding the freezing of the solution.
• Avoiding repeating heating and cooling cycles.
• The application of sterile handling techniques to reduce the risk of contamination.

Manufacturer instructions for commercial tesamorelin products may recommend using the solution relatively soon after reconstitution rather than storing it long-term [1]. In research and peptide-use settings, some users store reconstituted tesamorelin in the refrigerator for several days, although stability may vary depending on storage conditions and the type of diluent used.

Incorrect storage can increase the risk of peptide degradation, solution cloudiness, reduced efficacy, bacterial contamination, or solution thickening.

Clinical trials evaluating tesamorelin in the context of HIV-associated lipodystrophy, visceral fat reduction and NAFLD have used strictly controlled storage and preparation conditions during treatment periods ranging from 26 weeks to 12 months [4–8].

Why does Tesamorelin become jelly-like or cloudy?

Tesamorelin may become cloudy, thick, gel-like, or form clumps due to improper mixing, temperature instability, peptide degradation, contamination, or incorrect storage conditions [1–3]. Peptides are structurally sensitive molecules, and visible changes in solution can sometimes indicate instability or preparation issues.

A properly reconstituted tesamorelin solution should generally be clear and colourless when mixed. Cloudiness or gelling may occur when:

• The peptide is vortexed vigorously during reconstitution.
• Very hot or very cold water is used.
• The solution experiences repeated temperature changes.
• The peptide is exposed to excessive heat or direct sunlight.
• Incorrect diluents are being used.
• Contamination occurs during preparation.
• The peptide undergoes partial denaturation or aggregation. Aggregation means that peptide molecules start to stick together.

Some individuals report that tesamorelin becomes gel-like after refrigeration or prolonged storage. This may occur because peptide chains sometimes group together under certain temperature or concentration conditions. Highly concentrated solutions can increase the risk of thickening or hazing.

Poor quality bacteriostatic water, expired diluent, or contamination during reconstitution can also contribute to visible changes in the solution. If particulates, discolouration, persistent cloudiness or abnormal gel formation appear, many protocols recommend avoiding the use of the solution, as the peptide's stability or sterility may no longer be reliable.

Tesamorelin used in clinical trials was prepared under tightly controlled pharmaceutical conditions, and studies generally demonstrated good stability and tolerability with proper handling [4–8]. Injection site reactions were relatively common, however, serious issues related to formulation instability were not commonly reported in controlled studies.

Typical practices for handling peptides often include:

• Using sterile materials.
• Refrigerate after reconstitution.
• Avoid vigorous shaking.
• Limiting fluctuating temperature changes.
• Protect the vial from excessive heat and light.

Disclaimer

The content is for educational and scientific-informational purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or instruction for pharmaceutical preparation. Tesamorelin is a prescription medication requiring medical supervision. Reconstitution procedures, dilution volumes, storage conditions, and administration methods may vary depending on the manufacturer, formulation, and official product instructions. Tesamorelin should only be prepared, stored, and administered according to the manufacturer's guidelines and under the supervision of a qualified healthcare professional. Improper mixing, storage, injection technique, or unsupervised use of peptides may increase the risk of peptide degradation, contamination, adverse effects, or other complications.

References

1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available at: NCBI Bookshelf: Tesamorelin – An Overview
2. PubChem. (2025). Tesamorelin Compound Summary. National Centre for Biotechnology Information. Available at: PubChem: Tesamorelin Summary
3. Falutz J, Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicentre, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
4. Stanley TL, Feldpausch, M. N., Oh, J., et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomised clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
5. Stanley TL, Fourman, L. T., Feldpausch, M. N., et al. (2019). Effect of tesamorelin on non-alcoholic fatty liver disease in HIV-positive individuals: A randomised, double-blind, multicentre study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
6. Falutz J, Allas, S., Mamputu, J. C., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058